• Mashup Score: 0

    VJOncology brings you highlights in GI cancer from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!

    Tweet Tweets with this article
    • Don't miss our latest article on key trial updates in #GI from #ASCO21 📰 👩‍💻Featuring expert interviews on CheckMate 577, ClarIDHy, KEYNOTE-177 and more... Read here 👉https://t.co/vqgiHQ2NN8👈 @VJOncology @OncoAlert @ASCO #GIsm #Pancsm #CRCsm #NETsm #GCsm

  • Mashup Score: 0

    VJOncology brings you highlights in GI cancer from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!

    Tweet Tweets with this article
    • Catch up the latest trial updates in #GI from #ASCO21 📰 👩‍💻Featuring expert interviews on CheckMate 577, ClarIDHy, KEYNOTE-177 and more... Read here 👉https://t.co/nHQibusEjm👈 @VJOncology @OncoAlert @ASCO #GastrointestinalCancer #GIsm #Pancsm #CRCsm #NETsm #GCsm

  • Mashup Score: 1

    VJOncology brings you highlights in GI cancer from this year’s virtual American Society of Clinical Oncology (ASCO) annual meeting!

    Tweet Tweets with this article
    • 🗞 Read up on the latest trial updates in #GI from #ASCO21 Including CheckMate 577, ClarIDHy, KEYNOTE-177 and more... Read now 👉https://t.co/6LceK2iRcZ👈 @VJOncology @OncoAlert @ASCO #GastrointestinalCancer #GIsm #Pancsm #CRCsm #NETsm #GCsm

  • Mashup Score: 0
    Tweet Tweets with this article
    • This list via @ACCCBuzz includes our open and enrolling cellular checkpoint immunotherapy trial for patients with metastatic GI cancers: CRISPR TIL Cell Checkpoint Trial https://t.co/SZcm27AlSC https://t.co/eN5WYchAeT #crcsm #gcsm #pancsm #CRISPR #immunotherapy https://t.co/MCmhWeHrCh

  • Mashup Score: 1

    Skip to contentVisit Malignancies that affect the digestive tract’s different component sites are classified as gastrointestinal cancers. Including esophageal, gastric, bile duct, liver, pancreatic and colorectal cancer. View all videosJonathan Strosberg (@MoffittNews) discusses results from the midgut NET NETTER-1 trial: Median OS 11.7 months longer in pts receiving 177Lu- DOTATATE vs…

    Tweet Tweets with this article
    • 📢 The 2nd day of #WorldGI2021 has just ended and if you still want to know more about the latest advances in #GICancer, click below to see exclusive interviews and roundtable discussions: 👉 https://t.co/DteoVkEuZS 👈 @VJOncology @myESMO @OncoAlert #GIsm #CRCsm #GCsm https://t.co/nEGJP4hSAT